PercortenTM-V — veterinary medication

Overview

Source: Animal Drugs @ FDA

Proprietary name

PercortenTM-V

Active ingredient

Desoxycorticosterone Pivalate

Application type

NADA

Sponsor

Elanco US Inc.

Applications on record

1

First published

June 18, 2018

Adverse event reports

Source: openFDA VeDDRA

2,493

Reports mentioning this ingredient

July 29, 1998 – March 2, 2026

727

Classified serious

per reporter assessment

175

Lack of expected efficacy

resistance signal

8

Human operator exposure

needle-stick or splash

Not a risk measure. Veterinary adverse event reports are influenced by how many animals are treated, reporting practice and product age. Reports do not establish that the product caused the event, and a single report can cover an entire herd or flock. Attribution here is by active ingredient because the source dataset redacts brand names.

Attributed by active ingredient “DESOXYCORTICOSTERONE PIVALATE”. Green Book ingredient names and VeDDRA ingredient names do not always agree exactly, so attribution is approximate and labelled as such.

Reported reactions

Source: openFDA VeDDRA

Clinical signs coded in the VICH VeDDRA four-level hierarchy, most frequent first.

Reaction terms reported for this ingredient, by report count.
Reaction (VeDDRA term)	Reports	Relative frequency
Polydipsia	299
Polyuria	295
Vomiting	288
Depression	228
Anorexia	214
Immediate pain upon injection	206
Diarrhoea	203
Lethargy (see also Central nervous system depression in 'Neurological')	190
Other abnormal test result NOS	153
Lack of efficacy - NOS	149
High sodium-potassium ratio (Na:K ratio)	132
Death by euthanasia	111
Elevated serum alkaline phosphatase (SAP)	106
Weight loss	105
Weight gain	102
Vocalisation	95
Weakness	94
Underfilling, Vials	84
Elevated alanine aminotransferase (ALT)	84
Elevated creatinine	77

Species affected

Source: openFDA VeDDRA

Dog 2,233 Cat 18 Monkey 7 Human 3 Goat 1

Regulatory context

New Animal Drug Application (NADA). A pioneer approval evaluated for target animal safety, therapeutic effectiveness, manufacturing controls and — for food-producing species — human food safety including residue depletion.

Extra-label use in food-producing animals is governed by the Animal Medicinal Drug Use Clarification Act of 1994 (AMDUCA) and 21 CFR Part 530. It requires a valid veterinarian-client-patient relationship and is prohibited outright for certain drug classes. Withdrawal times are determined by FARAD, not by this index.

Sources for this page

Animal Drugs @ FDA	FDA CVM	Applications, sponsor, status, withdrawal
Animal & Veterinary Events	FDA CVM	VeDDRA adverse event aggregates by active ingredient